65,437 trials
Non-small Cell Lung Cancer (NSCLC)
Primary: Progression Free Survival (PFS) — 4.8; 2.6 month
Chronic Sinusitis
Primary: Safety: Device-related Adverse Events During Balloon Dilation Through 12 Months — 0 number of events
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 30 — -1.87; -1.54 percentage of total hemoglobin — p=0.0023
Prostate Cancer
Primary: Compare the Biodistribution of 11C-acetate Positron Emission Tomography (PET)/Computed Tomography (CT) Imaging in Tumor and Non Tumorous Regions of the Prostate — 4.4…
Obesity, Morbid
Primary: Change in Body Mass Index (BMI) — -0.9; 0.84 change in kg/m^2
Multiple Sclerosis · Spasticity
Primary: Incidence of Adverse Events as a Measure of Patient Safety — 126 participants
Healthy
Primary: Area Under the Plasma Concentration Curve (AUC) at Steady State for Metronidazole — 217686; 215809 ng*h/ml
Breast Cancer
Primary: Percentage of Patients Who Experience 30% Reduction in Average Pain Score From Baseline to 8 Weeks Due to Duloxetine Therapy. — 72.4 percentage of participants
Cervical Cancer · Cervical Intraepithelial Neoplasia Grade 1 · Human Papilloma Virus Infection
Primary: Complete Response - Clearance of Oncogenic Human Papillomavirus (HPV) and Complete Colposcopic, Histologic and Cytologic Clearance of Disease — 7; 6 participants
Bronchiolitis
Primary: Hospitalization Days — 5.8; 5.47 days
Pain
Primary: Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference From 0-8 Hours (SPRID 0-8) — 5.4; 29.8 Units on a scale — p=<0.001
Scleroderma, Systemic
Primary: Percent Change in Modified Rodnan Skin Score at 6 Months Compared to Baseline — -32 percentage of change in MRSS — p=0.005
Cataract
Primary: Phacodepth Required to Achieve Full Thickness Nuclear Crack — 2.5755 mm
Postoperative Cognitive Dysfunction
Primary: Mini Mental State Examination (MMSE) — 27; 26.769 scores on a scale — p=0.678
Type 2 Diabetes Mellitus
Primary: Number of Participants With Adverse Events. — 16; 3; 7; 5 participants